TickerGuard
Buy Day today: Neutral (60) Mixed market breadth · no major macro event
LCTX

Lineage Cell Therapeutics Inc

Healthcare · Biotechnology

0.9303$ +2.9% vs. previous close Closing price · As of: Oct 2, 2026

Statements

Balance Sheet

Lineage Cell Therapeutics Inc (LCTX) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Total Assets" came in at 106 million USD. Tick rows to compare them in a chart.

Income Statement Balance Sheet Cash Flow Ratios
Annual Quarterly
Amounts Change % Common size %
Last 12 Full history
Download as CSV

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Balance Sheet LCTX
Line item Q3 16 Q4 16 Q1 17 Q2 17 Q3 17 Q4 17 Q1 18 Q2 18 Q3 18 Q4 18 Q1 19 Q2 19 Q3 19 Q4 19 Q1 20 Q2 20 Q3 20 Q4 20 Q1 21 Q2 21 Q3 21 Q4 21 Q1 22 Q2 22 Q3 22 Q4 22 Q1 23 Q2 23 Q3 23 Q4 23 Q1 24 Q2 24 Q3 24 Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26
148 143 205 193 222 173 110 112 176 102 184 152 133 125 119 112 103 108 128 135 131 175 145 136 131 124 113 112 106 101 108 103 97 113 112 91 90 113 110 106
35 26 29 26 23 43 36 34 37 36 31 20 62 58 52 46 40 44 65 72 68 112 82 74 69 60 50 48 43 38 46 40 34 51 50 44 42 59 56 53
30 22 24 15 17 37 30 27 19 24 18 8.2 14 9.5 9.8 13 33 33 56 62 61 56 78 71 25 11 15 34 31 35 44 30 28 46 48 42 40 41 36 37
31 23 25 16 18 38 31 29 21 31 27 17 36 31 50 45 38 42 62 69 65 58 80 72 66 58 47 46 41 35 44 38 33 48 48 42 40 56 53 51
1.7 1.2 3.0 3.1 3.7 3.0 3.0 3.8 14 3.7 1.4 1.7 0.3 24 0.3 0.2 0.3 0.0 0.1 0.3 0.1 51 0.5 0.7 0.4 0.3 0.2 0.4 0.4 0.7 0.1 0.2 0.4 0.6 0.2 0.3 0.1 1.6 0.8 0.8
– – – 5.1 – 0.0 0.0 0.0 – 0.0 0.0 0.0 – – 0.0 – 0.0 – 0.0 – 0.0 – – 0.0 – 0.0 – 0.0 – – – – – – – – – – – –
4.7 – – – – – – – 5.1 5.8 8.9 8.7 8.8 8.2 7.5 7.1 4.8 5.6 5.1 5.0 4.7 4.9 4.5 3.9 4.7 5.7 5.6 5.3 – – – – – – – – – – – –
– – – – – – – – – – 13 13 13 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11
11 10 8.6 8.1 7.5 6.9 6.3 5.7 3.6 3.1 50 49 49 48 48 47 47 47 47 47 47 47 47 47 47 47 47 47 47 47 47 47 47 47 47 32 32 32 32 32
11 12 16 15 13 9.0 7.9 7.5 6.5 9.4 22 20 17 14 14 14 13 13 11 11 12 84 59 54 54 52 44 40 39 39 37 36 32 36 34 44 69 69 57 46
8.3 8.9 8.8 14 6.0 6.9 5.8 5.8 4.5 6.8 8.7 7.9 6.2 6.5 7.0 7.5 7.8 7.8 6.6 6.8 8.8 47 25 25 23 19 17 16 16 18 17 15 14 14 13 11 9.4 11 8.1 8.0
0.6 1.1 1.2 2.7 0.1 0.4 0.3 0.3 0.3 0.3 1.0 1.0 1.1 1.2 1.2 1.2 1.0 1.3 1.3 0.8 0.8 0.8 0.8 0.6 0.6 1.0 1.0 1.0 0.9 0.9 1.1 1.1 1.1 1.2 1.2 1.0 1.1 0.9 0.9 1.0
1.7 1.6 1.1 0.8 0.5 0.9 0.7 1.2 0.7 2.4 1.4 2.0 1.9 5.2 3.5 3.4 3.2 2.6 2.8 2.7 3.5 3.5 3.0 2.6 2.9 2.4 3.0 2.2 2.4 2.1 2.2 2.4 1.6 1.2 2.0 1.5 1.5 2.3 5.6 1.5
1.1 – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – –
119 118 187 176 198 163 100 101 171 94 163 133 117 113 106 99 91 96 118 125 121 92 87 83 79 73 70 73 68 63 72 68 66 78 79 48 22 45 54 61
-191 -196 -147 -159 -144 -216 -279 -284 -217 -262 -222 -252 -269 -273 -282 -288 -296 -294 -295 -300 -308 -337 -344 -351 -357 -363 -368 -373 -380 -385 -391 -397 -400 -403 -408 -438 -468 -467 -472 -470
104 103 107 111 115 127 127 127 127 127 133 150 150 150 150 150 150 150 159 163 168 168 170 170 170 170 170 171 175 173 183 189 189 200 226 228 229 230 261 261

Showing the most recent 40 periods — older statements are on file for this stock.

Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?